Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Wolff, I; May, M; Hoschke, B; Zigeuner, R; Cindolo, L; Hutterer, G; Schips, L; De Cobelli, O; Rocco, B; De Nunzio, C; Tubaro, A; Coman, I; Feciche, B; Truss, M; Dalpiaz, O; Figenshau, RS; Madison, K; Sánchez-Chapado, M; Santiago Martin, MD; Salzano, L; Lotrecchiano, G; Shariat, SF; Hohenfellner, M; Waidelich, R; Stief, C; Miller, K; Pahernik, S; Brookman-May, S; Members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group.
Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.
Eur J Surg Oncol. 2016; 42(5):744-750
Web of Science PubMed FullText FullText_MUG

 

Authors Med Uni Graz:
Dalpiaz Orietta
Hutterer Georg C.
Schips Luigi
Zigeuner Richard
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Since there is still an unmet need for potent adjuvant strategies for renal cancer patients with high progression risk after surgery, several targeted therapies are currently evaluated in this setting. We analyzed whether inclusion criteria of contemporary trials (ARISER, ASSURE, SORCE, EVEREST, PROTECT, S-TRAC, ATLAS) correctly identify high-risk patients. The study group comprised 8873 patients of the international CORONA-database after surgery for non-metastatic renal cancer without any adjuvant treatment. Patients were divided into potentially eligible high-risk and assumable low-risk patients who didn't meet inclusion criteria of contemporary adjuvant clinical trials. The ability of various inclusion criteria for disease-free survival (DFS) prediction was evaluated by Harrell's c-index. During a median follow-up of 53 months 15.2% of patients experienced recurrence (5-year-DFS 84%). By application of trial inclusion criteria, 24% (S-TRAC) to 47% (SORCE) of patients would have been eligible for enrollment. Actual recurrence rates of eligible patients ranged between 29% (SORCE) and 37% (S-TRAC) opposed to <10% in excluded patients. Highest Hazard Ratio for selection criteria was proven for the SORCE-trial (HR 6.42; p < 0.001), while ASSURE and EVEREST reached the highest c-index for DFS prediction (both 0.73). In a separate multivariate Cox-model, two risk-groups were identified with a maximum difference in 5-year-DFS (94% vs. 61%). Results of contemporary adjuvant clinical trials will not be comparable as inclusion criteria differ significantly. Risk assessment according to our model might improve patient selection in clinical trials by defining a high-risk group (28% of all patients) with a 5-year-recurrence rate of almost 40%. Copyright © 2016 Elsevier Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Clinical Trials, Phase III as Topic -
Diagnostic Imaging -
Disease Progression -
Female -
Humans -
Kidney Neoplasms - surgery
Male -
Middle Aged -
Neoplasm Recurrence, Local -
Neoplasm Staging -
Nephrectomy -
Quality Improvement -
Risk Assessment -
Treatment Outcome -

Find related publications in this database (Keywords)
Renal cell cancer
Nephrectomy
Disease recurrence
Adjuvant therapy
Phase-3-trials
Targeted agents
© Med Uni GrazImprint